Oxygen Of The Saccharide Radical Is Directly Bonded To A Nonsaccharide Heterocyclic Ring Or A Fused- Or Bridged-ring System Which Contains A Nonsaccharide Heterocyclic Ring (e.g., Coumermycin, Novobiocin, Etc.) Patents (Class 435/75)
-
Patent number: 5085982Abstract: The invented method utilizes a signal amplification system comprising living cells which are specifically provided with the ability to survive, reproduce and be detected in the event that a target molecule is present. The method comprises first the step of binding a target molecule to a substratum. In the second step a phagemid is prepared which is capable of transfecting a cell enabling such transfected cell to produce a signal, such as color or light. The phagemid is then provided with a means for binding to a probe, thus forming a phagemid complex.The probe may also be provided with a means of binding to the phagemid complex. This modified probe is then hybridized with the target molecules bound to the substratum. Thereafter, the phagemid complex is hybridized with the modified probe and specific binding occurs between the phagemid complex and the modified probe thus forming a substrutum-target-probe phagemid complex.Type: GrantFiled: June 12, 1986Date of Patent: February 4, 1992Assignee: City of HopeInventor: Douglas H. Keith
-
Patent number: 5077206Abstract: The invention provides a process for preparing L-rhamnose by hydrolyzing a rhamnosidic bond of a glycoside having rhamnose in a terminal position, by enzymatically hydrolyzing the glucoside with an enzyme combination comprising biological structural material degrading enzyme and a naringinase preparation which has a higher rhamnosidase activity than beta-glucosidase activity. Preferably the enzyme combination having rhamnosidase activity together with additional enzyme activity is a selected partially purified enzyme preparation having high rhamnosidase activity and low glucosidase activity together with biological structural material degrading activity. More preferably the additional enzyme activity is derived from an enzyme of the group consisting of protease, lipase, pectinase, cellulase and hemicellulase.Type: GrantFiled: November 21, 1988Date of Patent: December 31, 1991Assignee: Unilever Patent Holdings B.V.Inventors: Peter S. J. Cheetham, Michael A. Quail
-
Patent number: 5070013Abstract: Monoclonal antibodies and compositions thereof are provided for detecting, measuring, and immunopurifying human GM-CSF.Type: GrantFiled: May 31, 1988Date of Patent: December 3, 1991Assignee: Schering CorporationInventors: John S. Abrams, Robert E. Van Dyke
-
Patent number: 5070015Abstract: Incubation of 13-deoxy ivermectin aglycone with a species of B. subtilis and of S. griseus results in the production of 13-.beta. ivermectin monoglucopyranoside as the major product and of 5-.beta. ivermectin monoglucopyranoside as the minor product.Type: GrantFiled: October 15, 1990Date of Patent: December 3, 1991Assignee: Merck & Co., Inc.Inventors: Brian R. Petuch, Shieh-Shung T. Chen, Edward S. Inamine, Raymond F. White
-
Patent number: 5068198Abstract: Assay methods and compositions are provided for determining an analyte in a sample suspected of containing the analyte. The composition comprises in a novel single liquid reagent at least one specific binding pair (sbp) member and its complementary member wherein at least one sbp member is reversibly confined in a material that temporarily renders the confined sbp member incapable of binding with its complementary sbp member. At least one of the sbp members is bound to a member of a signal producing system capable of producing a detectable signal in relation to the amount of analyte in the sample. The confinement is reversed, any remaining members of the signal producing system are added, and the signal produced in relation to the amount of analyte is measured. Examples of the confining material are lipid bilayers, cells and gels.Type: GrantFiled: January 13, 1989Date of Patent: November 26, 1991Assignee: Syntex (U.S.A.) Inc.Inventors: Ian Gibbons, Edwin F. Ullman, Philip L. Felgner
-
Patent number: 5066580Abstract: Novel xanthene dyes are disclosed which excite in the range of 450-650 nm and which will emit to the red of fluoroscein. These dyes may be coupled to tagging agents, such as monoclonal antibodies, and used to detect cells in a sample.Type: GrantFiled: February 16, 1990Date of Patent: November 19, 1991Assignee: Becton Dickinson and CompanyInventor: Linda Lee
-
Patent number: 5061624Abstract: Disclosed are antibiotics BU-3608 FA-1 and FA-2 and alkyl derivatives thereof. These compounds are useful as antifungal agents. BU-3608 FA-1 and FA-2 are produced from Actinomadura hibisca in a medium containing a source of D-serine.Type: GrantFiled: August 20, 1990Date of Patent: October 29, 1991Assignee: Bristol-Myers CompanyInventors: Yosuke Sawada, Masatoshi Kakushima, Maki Nishio, Takeo Miyaki, Toshikazu Oki
-
Patent number: 5055453Abstract: Two new antibiotics which are now nominated as benanomicin A and benanomicin B, respectively, are fermentatively produced by the cultivation of a new microorganism, designated as MH193-16F4 strain, of Actinomycetes. Benanomicins A and B each show antifungal activity and are useful as a therapeutic antifungal agent. A new compound, dexylosylbenanomicin B is now produced by chemical conversion of benanomicin B, and this semi-synthetic antibiotic also shows antifungal activity and is useful as a therapeutic antifungal agent.Type: GrantFiled: October 31, 1988Date of Patent: October 8, 1991Assignee: Zaidan Hojin Biseibutsu Kagaku Kenkyu KaiInventors: Tomio Takeuchi, Takeshi Hara, Masa Hamada, Shinichi Kondo, Masaji Sezaki, Haruo Yamamoto, Shuichi Gomi
-
Patent number: 5051356Abstract: A specific binding composition comprises a specific binding species and one or more water-soluble proteins or carbohydrates, substantially none of which has a pI greater than about 5. This composition provides improved sensitivity with lower background in diagnostic tests. Preferably, the species is labeled for detection, for example, with an exzyme. The composition can be included with a dye-providing composition in a diagnostic test kit for use in diagnostic methods.Type: GrantFiled: June 13, 1988Date of Patent: September 24, 1991Assignee: Eastman Kodak CompanyInventors: Harold C. Warren, III, Brian A. Snyder
-
Patent number: 5045535Abstract: The present invention provides a process for the production of a polysaccharide matrix to which haptens are covalently bound, wherein polysaccharide-containing material is rendered alkaline, dried to a water content of less than 5% and then reacted in an anhydrous medium with a hapten containing at least one activated functional group.The present invention also provides a device for carrying out this process, which comprises a winding core (3) in a container (1) for a reaction solution which has a tube (11), provided on its wall with a plurality of openings (7) and closed on one end (9), for the reception of a winding (13) of the material to be treated and two axial end walls (15, 17) for sealing off the axial ends of the winding (13) and feeds the reaction solution from the container (1) into the other end (21) of the tube (11) by means of a circulating pump cycle (19).Type: GrantFiled: December 9, 1988Date of Patent: September 3, 1991Assignee: Boehringer Mannheim GmbHInventor: Thomas Mang
-
Patent number: 5039607Abstract: A method is disclosed for conducting an assay for an analyte. The method comprises causing a specific binding pair member in a first aqueous medium to become bound to a first bibulous member by contacting a portion of the first bibulous member with the medium. The first bibulous member is in liquid receiving relationship with an absorbent member. The contacting is carried out under conditions wherein the first medium traverses the first bibulous member and at least a portion of the absorbent member by capillary action. The method further comprises causing the first bibulous member to come into liquid receiving relationship with a second bibulous member. A reagent in a second aqueous medium is absorbed by and preferably becomes a non-diffusively bound to the second bibulous member in relation to the presence of analyte in the first medium.Type: GrantFiled: May 17, 1988Date of Patent: August 13, 1991Assignee: Syntex (U.S.A.) Inc.Inventors: Carl N. Skold, Armen B. Shanafelt, Vartan Ghazarossian, Edwin F. Ullman
-
Patent number: 5024935Abstract: A dye-providing composition comprises a water-soluble or -dispersible polymer, such as a vinylpyrrolidone polymer, and an imidazole leuco dye capable of providing a dye in the presence of hydrogen peroxide and a peroxidative substance. The weight ratio of polymer to leuco dye is from about 10,000:1 to about 100:1. The dye-providing composition can be included with a peroxidase substrate in a diagnostic test kit. A method for the determination of a ligand can be carried out using a peroxidase labeled-receptor for the ligand and the dye-providing composition described above. The method is particularly useful for the determination of human chorionic gonadotropin (hCG).Type: GrantFiled: December 18, 1987Date of Patent: June 18, 1991Assignee: Eastman Kodak CompanyInventors: Gregory J. McClune, John F. Bishop
-
Patent number: 5024950Abstract: A macrolactam disaccharide isolated from an antimicrobial complex 530 produced in fermentation under controlled conditions using a biologically pure culture of the microorganism Actinomadura fulva subsp. indica ATCC 53714.Type: GrantFiled: January 3, 1990Date of Patent: June 18, 1991Assignee: Schering CorporationInventor: Ann C Horan
-
Patent number: 5019498Abstract: A high molecular hyaluronic acid which is an important factor in the diagnosis of inflammations such as rheumatism or diseases such as cancer is assayed as a complex of sandwich structure in which a hyaluronic acid binding protein is coupled to the hyaluronic acid of interest at two or more sites of binding without the need to employ a competitive reaction as in the prior art techniques of assay. The assay method of the present invention does not require a purified form of hyaluronic acid as a reagent and permits as small as 10 ng of a high molecular hyaluronic acid to be detected or quantified by a very simple operation.Type: GrantFiled: March 1, 1988Date of Patent: May 28, 1991Assignee: Chugai Seiyaku Kabushiki KaiskaInventor: Kenji Chichibu
-
Patent number: 5017474Abstract: An aqueous wash solution is buffered to a pH of from about 5 to about 9 and contains at least about 0.01 weight percent of a compound comprising a dodecyl sulfate anion and an alkali metal or ammonium cation, such as sodium dodecyl sulfate. This wash solution is particularly useful in a method for the determination of an immunological ligand. Particularly, it is useful for washing the immunological complex formed between the ligand and a receptor molecule therefor. Unreacted materials can be readily separated from the complex by the washing, particularly if the separation is carried out using a filtration membrane in a test device. a test kit for ligand determination comprises the wash solution as well as one or more receptors for the ligand, at least one of which is labeled for detection. This kit is particularly useful for measuring human chorionic gonadotropin (hCG) as an early indicator of pregnancy.Type: GrantFiled: February 12, 1988Date of Patent: May 21, 1991Assignee: Eastman Kodak CompanyInventors: Gregory J. McClune, Margaret J. Smith-Lewis
-
Patent number: 5015578Abstract: A new antitumor antibiotic designated BMY-41950 is produced by fermentation of Streptomyces staurosporeus ATCC 55006 or Streptomyces hygroscopicus ATCC 53730. The BMY-41950 antibiotic exhibits both antimicrobial and antitumor activities.Type: GrantFiled: February 20, 1990Date of Patent: May 14, 1991Assignee: Bristol-Myers Squibb CompanyInventors: Daniel Schroeder, Kin S. Lam, Jacqueline Mattei, Grace A. Hesler
-
Patent number: 5015588Abstract: An assay method for the detection of Factor XIII in plasma is disclosed in which a primary amine derivative of biotin such as preferably 5-(biotinamido) pentylamine is incubated with a glutamine substrate and activated Factor XIII (Factor XIIIa) to form a biotinylated product which may be measured by convention detection assays. In a preferred embodiment, the biotinylated product is bound to a well in a microtiter plate or other solid support and the product is measured by a colorimetric assay which may be read by an automated spectrophotometric plate reader.Type: GrantFiled: October 29, 1987Date of Patent: May 14, 1991Assignee: The Samuel Roberts Noble Foundation, Inc.Inventors: Kyung Lee, Manford K. Patterson, Jr., Paul J. Birckbichler
-
Patent number: 5011770Abstract: Picogram amounts of DNA can be detected in a sample by the use of high-affinity, single-stranded DNA binding proteins. The assay is applicable not only to pure DNA samples but also to samples containing significant amounts of protein.Type: GrantFiled: July 24, 1990Date of Patent: April 30, 1991Assignee: Molecular Devices, Inc.Inventors: Viola T. Kung, Peter A. Nagainis, Edward L. Sheldon, III
-
Patent number: 5006473Abstract: The electrophoresis method of the present invention employs a media which contains uniformly dispersed liposomes of phospholipid, or combinations of phospholipid and neutral lipid, which contain chromogenic materials or dye precursers. After electrophoresis of a test sample, the liposomes are lysed and the chromogen or dye material released. The chromogen or dye can be any signal producing substance including a chromogenic agent, and enzyme, a fluorogenic agent, or a chemiluminescent agent, but a detectable signal occurs only where the staining material is in close proximity to specific enzymes, effectors, analytes, or other color-inducing agents which have migrated through the gel during electrophoresis.Type: GrantFiled: August 9, 1988Date of Patent: April 9, 1991Assignee: Abbott LaboratoriesInventors: Stanley R. Bouma, Lawrence J. Blecka, Philip Miller
-
Patent number: 5004699Abstract: A method for detecting organisms such as fungi and yeast in a sample attached to a solid phase, by detecting the presence of chitin in using lectin or anti-chitin antibodies.Type: GrantFiled: October 24, 1989Date of Patent: April 2, 1991Assignee: SRI InternationalInventor: Mark A. Winters
-
Patent number: 5003050Abstract: A water-soluble luminescent compound having repeating units of the formula: ##STR1## The product, which is a polymer having repeating units comprising diazo-linked luminol and hydroxyindole, is referred to as diazoluminomelanin (DALM), since one of the precursors to this product, 3-amino-L-tyrosine (3AT) is closely related to the biological substrates which are converted into melanin.Also provided is a method for preparing DALM which comprises reacting 3AT with an alkali metal nitrite, and reacting the resulting diazonium salt with luminol.DALM can be used for chemiluminescent immunoassays for biological and chemical agents; in radiofrequency and ionizing radiation dosimeters; and for RNA/DNA hybridization assays for viruses and genetic detection.Type: GrantFiled: March 7, 1990Date of Patent: March 26, 1991Assignee: The United States of America as represented by the Secretary of the Air ForceInventors: Johnathan L. Kiel, Gerald J. O'Brien
-
Patent number: 5002885Abstract: A detectable molecule of the formulaA.sup.3 --(--X--R.sup.1 --E--Det.sup.b).sub.mwhere A.sup.3 is A.sup.2 or a polymer, where A.sup.3 has at least one modifiable reactive group selected from the group consisting of amino, hydroxy, cis OH, halides, aryl, imidazoyl, carbonyl, carboxy, thiol or a residue comprising an activated carbon; --X-- is selected from the group consisting of ##STR1## a C.sub.1 -C.sub.10 branched or unbranched alkyl or aralkyl, which may be substituted by --OH; --Y-- is a direct bond to --E--, or --Y-- is --E--R.sup.2 -- where R.sup.2 is a C.sub.1 -C.sub.10 branched or unbranched alkyl; Z.sub.a is chlorine, bromine or iodine; E is O, NH or an acylic divalent sulfur atom; Det.sup.b is a chemical moiety capable of being detected, preferably comprising biotin or a metal chelator of the formula: ##STR2## or the 4-hydroxy or acyloxy derivative thereof, where R.sup.3 is C.sub.1 -C.sub.4 alkyl or CH.sub.Type: GrantFiled: April 24, 1990Date of Patent: March 26, 1991Assignee: Enzo Biochem, Inc.Inventor: Jannis G. Stavrianopoulos
-
Patent number: 5001049Abstract: The invention relates to a method for determining HIV (human immunodeficiency virus) specific antibodies. A sample is incubated with a solid phase, to which streptavidin is bound in a way to make 0.1-2.5 .mu.g streptavidin per ml of reaction volume available for binding, a biotinylated polypeptide, and a labelled receptor which binds to HIV specific antibodies. The biotinylated polypeptide contains at least one of the amino acid sequences ##STR1## and is from 7 to 50 amino acids long. Following complex formation onto the solid phase, solid and liquid phase are separated, and label is measured in one of these.Type: GrantFiled: January 19, 1990Date of Patent: March 19, 1991Assignee: Boehringer Mannheim GmbHInventors: Christian Klein, Hubert Bayer
-
Patent number: 4992425Abstract: Disclosed herein are antibiotic BU-3608 D and E isolated from Actinomadura hibisca. These compounds are active antifungal agents.Type: GrantFiled: June 7, 1988Date of Patent: February 12, 1991Assignee: Bristol-Myers CompanyInventors: Maki Nishio, Yosuke Sawada, Takeo Miyaki, Toshikazu Oki
-
Patent number: 4990442Abstract: An assay for an analyte wherein sample is applied to a support capable of binding proteins by essentially only hydrogen bonding and fixed on the support. Analyte may be determined on the support by use of a suitable tracer. A preferred support is amphiphilic cellulose acetate. In an immunoassay, it is possible to determine analyte without use of a supported ("capture") antibody.Type: GrantFiled: December 14, 1987Date of Patent: February 5, 1991Assignee: ChemetronInventor: G. B. Del Campo
-
Patent number: 4990497Abstract: Novel antibiotic herein designated as BU-3608, BU-3608 B, and BU-3608 C are produced by fermentation of Actinomadura hibisca Strain No. P157-2, ATCC 53557, and Strain No. Q278-4, ATCC 53646. The antibiotics possess antifungal and antiviral activities.Type: GrantFiled: June 15, 1989Date of Patent: February 5, 1991Inventors: Toshikazu Oki, Kyoichiro Saitoh, Kozo Tomatsu, Koji Tomita, Masataka Konishi, Takeo Miyaki, Mitsuaki Tsunakawa, Maki Nishio
-
Patent number: 4988629Abstract: Incubation media intended for solid-phase immunometric assays and containing lactoferrin are described. Compared with the media used hitherto, these incubation media have the advantage that they prevent, especially in the case where heated sample material is used in the assays, false results on determination of antigens or antibodies.Type: GrantFiled: November 10, 1987Date of Patent: January 29, 1991Assignee: Behringwerke AktiengesellschaftInventors: Hans-Detlef Dopatka, Rudolf Schmidtberger
-
Patent number: 4988627Abstract: An immunoassay test device is disclosed with dried reagent drops applied to a sloping side wall of a reaction wall. A method of applying them as liquid drops is also described, wherein the slope of the side wall, and the composition and volume of the liquid drop are selected to insure that the liquid drops do not flow down to the bottom of the well.Type: GrantFiled: December 18, 1987Date of Patent: January 29, 1991Assignee: Eastman Kodak CompanyInventor: Margaret J. Smith-Lewis
-
Patent number: 4987072Abstract: The invention relates to cyclic antibiotics of formula ##STR1## wherein the prefix R represents that the substituents on the adjacent carbon atom are in the R configuration; the prefix S represents that the substituents on the adjacent carbon atom are in the S configuration; R.sub.1 is hydrogen or hydroxy and R.sub.2 is hydroxy or .beta.-glucopyranosyloxy, and to the hydrates and salts thereof, especially pharmaceutically acceptable salts.The compounds of formula I are prepared by fermentation using the strain So ce 12 (NCIB 12134) of the species Sorangium celulosum and are effective antiobiotics.Type: GrantFiled: September 11, 1986Date of Patent: January 22, 1991Assignee: Gesellschaft fur Biotechnologische Forschung GmbHInventors: Hans Reichenbach, Gerhard Hofle, Hermann Augustiniak, Norbert Bedorf, Klaus Gerth, Herbert Irschik, Rolf Jansen, Brigitte Kunze, Dietmar Schomburg, Heinrich Steinmetz, Wolfram Trowitzsch-Kienast, Victor Wray
-
Patent number: 4977143Abstract: Antibacterial and antitumor agents designated LL-E333288.epsilon.-I and LL-E33288.epsilon.-Br and their production by strains of Micromonospora echinospora ssp. calichensis designated NRRL-15839, NRRL-15975 and NRRL-18149, are disclosed.Type: GrantFiled: February 29, 1988Date of Patent: December 11, 1990Assignee: American Cyanamid CompanyInventors: William J. McGahren, George A. Ellestad
-
Patent number: 4973673Abstract: Disclosed are antibiotics BU-3608 FA-1 and FA-2 and alkyl derivatives thereof. These compounds are useful as antifungal agents. BU-3608 FA-1 and FA-2 are produced from Actinomadura hibisca in a medium containing a source of D-serine.Type: GrantFiled: November 10, 1988Date of Patent: November 27, 1990Assignee: Bristol-Myers CompanyInventors: Yosuke Sawada, Masatoshi Kakushima, Maki Nishio, Takeo Miyaki, Toshikazu Oki
-
Patent number: 4962037Abstract: A method is provided for the rapid base sequencing of DNA or RNA fragments wherein a single fragment of DNA or RNA is provided with identifiable bases and suspended in a moving flow stream. An exonuclease sequentially cleaves individual bases from the end of the suspended fragment. The moving flow stream maintains the cleaved bases in an orderly train for subsequent detection and identification. In a particular embodiment, individual bases forming the DNA or RNA fragments are individually tagged with a characteristic fluorescent dye. The train of bases is then excited to fluorescence with an output spectrum characteristic of the individual bases. Accordingly, the base sequence of the original DNA or RNA fragment can be reconstructed.Type: GrantFiled: October 7, 1987Date of Patent: October 9, 1990Assignee: United States of AmericaInventors: James H. Jett, Richard A. Keller, John C. Martin, Robert K. Moyzis, Robert L. Ratliff, E. Brooks Shera, Carleton C. Stewart
-
Patent number: 4904644Abstract: A macrolactam disaccharide isolated from an antimicrobial complex 530 produced in fermentation under controlled conditions using a biologically pure culture of the microorganism Actinomadura fulva subsp. indica ATCC 53714.Type: GrantFiled: August 3, 1988Date of Patent: February 27, 1990Assignee: Schering CorporationInventors: Vinod R. Hedge, Ann C. Horan, Arthur H. King, Frank A. Gentile, Mahesh G. Patel, Gerald H. Wagman
-
Patent number: 4870165Abstract: Novel antibiotic herein designated as BU-3608, BU-3608 B, and BU-3608 C are produced by fermentation of Actinomadura hibisca Strain No. P157-2, ATCC 53557, and Strain No. Q278-4, ATCC 53646. The antibiotics possess antifungal and antiviral activities.Type: GrantFiled: November 2, 1987Date of Patent: September 26, 1989Assignee: Bristol-Myers CompanyInventors: Toshikazu Oki, Kyoichiro Saitoh, Kozo Tomatsu, Koji Tomita, Masataka Konishi, Takeo Miyaki, Mitsuaki Tsunakawa, Maki Nishio
-
Patent number: 4734403Abstract: The present invention relates to a membrane polysaccharide of bacterial origin having the following quantitative analytical composition:______________________________________ galactose content 66 .+-. 6% content of hexoses other than galactose <1% hexosamine (glucosamine) content 8.5 .+-. 2% amino acid content 5 .+-. 2% fatty acid content <1% nucleic acid content <0.005% protein content <0.03% and molecular weight: 90,000 .+-. 10,000.Type: GrantFiled: August 29, 1985Date of Patent: March 29, 1988Assignee: P.F. MedicamentInventors: Lucien Dussourd D'Hinterland, Gerard Normier, Anne-Marie Pinel
-
Patent number: 4734492Abstract: Disclosed is a novel macrolide antibiotic, M 119, of the formula (A): ##STR1## wherein the substituent R designates either (a) or (d): (a) R: H(d) R: OH.The antibiotic M 119 has antimicrobial activity, particularly against Gram-positive bacteria, typical pathogenic bacteria falling under Gram-negative bacteria such as Haemophilus influenzae, and mycoplasmas, and is effective against infections induced by such bacteria.Type: GrantFiled: July 11, 1986Date of Patent: March 29, 1988Assignee: Kirin Beer Kabushiki KaishaInventors: Hiroyuki Tanba, Kazuyoshi Adachi, Tomiko Kawasaki
-
Patent number: 4687764Abstract: A hypotriglyceridemically active polysaccharide having the following characteristics:(a) Specific rotatory power:[.alpha.].sub.D.sup.29 =+190.1(1.8 w/v % solution)(b) Molecular weight by gel filtration:14,000.+-.3,000(c) Sugar composition (weight percent by gas chromatography)glucose: 70.3rhamnose: 13.7uronic acid: 16.0(d) Acid-base characteristic:neutral polysaccharides(e) Physiological characteristics:capable of reducing the blood triglyceride in mammals.This hypotriglyceridemically active polysaccharide can be prepared by cultivating a microorganism belonging to the genus Streptococcus in an adequate culture medium therefor; and collecting the hypotriglyceridemically active polysaccharide from the cultured cells of the microorganism and/or the supernatant of the culture broth.Type: GrantFiled: July 20, 1984Date of Patent: August 18, 1987Assignee: Kabushiki Kaisha Advance Kaihatsu KenkyujoInventors: Yasuo Kawai, Kazunaga Yazawa
-
Patent number: 4683201Abstract: New polyether antibiotic A80190, its acyl and alkyl ester, acyl ester and urethane derivatives, and salts thereof, are useful antibacterial and anticoccidial agents and increase feed-utilization efficiency in animals. Methods of making A80190 by culture of Actinomadura oligospora NRRL 15877 and synergistic compositions of the A80190 compounds with nicarbazin, 4,4'-dinitrocarbanilide, certain napthalenamine and benzenamine compounds and metichlorpindol are also provided.Type: GrantFiled: October 15, 1985Date of Patent: July 28, 1987Assignee: Eli Lilly and CompanyInventors: Robert L. Hamill, Raymond C. Yao
-
Patent number: 4673642Abstract: The plasmid p SVH 1, which is obtained from Streptomyces venezuelae DSM 40755 and which has a molecular weight of 8.4 megadaltons, a contour length of 4.1 .mu.m and a molecular size of 12.6 kilobases, and its use for the construction of a vector and for cloning foreign DNA in suitable host organisms.Type: GrantFiled: August 20, 1984Date of Patent: June 16, 1987Assignee: Hoechst AktiengesellschaftInventors: Alfred Puhler, Wolfgang Wolleben, Michael Leineweber
-
Patent number: 4672033Abstract: There is presented antibiotic compounds designated as Antibiotics X-14889 A, C and D of the formulas ##STR1## wherein (for X-14889A) R.sub.1 is methyl, R.sub.2 is methyl, R.sub.3 is hydrogen, R.sub.4 is methyl and R.sub.5 is hydrogen or (for X-14889C) R.sub.1 is hydrogen, R.sub.2 is methyl, R.sub.3 is hydrogen, R.sub.4 is methyl and R.sub.5 is CO.sub.2 H or ##STR2## and the pharmaceutically acceptable salts thereof. The compounds exhibit antimicrobial activity and one of the compounds X-14889C also exhibits activity against Treponema hyodysenteriae (in vitro), Plasmodium berghei and as food efficiency enhancers in ruminants.Also presented is a process to produce the above compounds and another known component Antibiotic X-14889B.Type: GrantFiled: May 23, 1985Date of Patent: June 9, 1987Assignee: Hoffmann-La Roche Inc.Inventors: Chao-Min Liu, John Westley
-
Patent number: 4650765Abstract: This invention relates to two new antibacterial and anti-tumor agents designated LL-BO1208.alpha. and LL-BO1208.beta. produced during microbiological fermentation, under controlled conditions, using the novel microorganism Streptoverticillium stramineum and mutants thereof.Type: GrantFiled: July 30, 1985Date of Patent: March 17, 1987Assignee: American Cyanamid CompanyInventors: Jane P. Kirby, Amedeo A. Fantini, Donald B. Borders, Raymond T. Testa, John H. E. J. Martin, deceased
-
Patent number: 4637981Abstract: Glycopeptide antibiotic A-4696G is produced by culturing Actinoplanes missouriensis mutant strain ATCC 31681 under submerged aerobic fermentation conditions, and is recovered from the fermentation broth by resin adsorption and chromatographic purification. A-4696G inhibits the growth of bacteria pathogenic to man and animals and also enhances the growth of ruminants by increasing feed utilization.Type: GrantFiled: March 26, 1984Date of Patent: January 20, 1987Assignee: Eli Lilly and CompanyInventors: Charles L. Hershberger, Kurt E. Merkel, Robert E. Weeks, Gene M. Wild
-
Patent number: 4626503Abstract: Antitumor agents LL-D49194.alpha..sub.1, LL-D49194.beta..sub.1, LL-D49194.beta..sub.2, LL-D49194.beta..sub.3, LL-D49194.gamma., LL-D49194.delta., LL-D49194.epsilon., LL-D49194.xi., LL-D49194.eta., LL-D49194.omega., LL-D49194.omega..sub.2 and LL-D49194.omega..sub.3.Type: GrantFiled: February 14, 1985Date of Patent: December 2, 1986Assignee: American Cyanamid CompanyInventors: May D. Lee, Amedeo A. Fantini, David P. Labeda, William M. Maiese, Raymond T. Testa, Donald B. Borders
-
Patent number: 4572895Abstract: A novel antibiotic complex designated BBM-2478 is produced by fermentation of an actinomycete strain J907-21 (ATCC 39417). The complex may be separated chromatographically into two bioactive components designated BBM-2478A and BBM-2478B. The BBM-2478A component displays both antibacterial and antitumor activity while the BBM-2478B component has antibacterial activity.Type: GrantFiled: February 19, 1985Date of Patent: February 25, 1986Assignee: Bristol-Myers CompanyInventors: Masataka Konishi, Koko Sugawara, Takeo Miyaki, Hiroshi Kawaguchi
-
Patent number: 4560662Abstract: The fermentation of a substrate selected among erythronolide B, erythronolide A and erythronolide A oxime with a novel mutant, Streptomyces antibioticus ATCC 31771, obtained from an industrial stock for the production of oleandomycin, said novel mutant being incapable of producing the same oleandomycin, permits novel macrolide antibiotics to be produced, having not only an activity range like that of erythromycin, but characterized by a greater stability in acidic environment, whereby for the administration of the antibiotic it is no longer necessary to have recourse to esters and/or salts highly toxic for the organism.Type: GrantFiled: November 3, 1983Date of Patent: December 24, 1985Assignee: Pierrel S.p.A.Inventors: Leonardo M. Cappelletti, Roberto Spagnoli, Luciano Toscano
-
Patent number: 4558009Abstract: Antibiotic A-51568 is produced by submerged, aerobic fermentation of new Nocardia orientalis NRRL 15232. The antibiotic is effective against gram-positive organisms.Type: GrantFiled: December 27, 1983Date of Patent: December 10, 1985Assignee: Eli Lilly and CompanyInventors: LaVerne D. Boeck, Marvin M. Hoehn, Gary G. Marconi
-
Patent number: 4558008Abstract: The novel glycopeptide antibiotic A-51568B is produced by submerged, aerobic fermentation of Nocardia orientalis NRRL 15232. A-51568B demonstrates antibiotic activity against gram-positive bacteria.Type: GrantFiled: December 13, 1983Date of Patent: December 10, 1985Assignee: Eli Lilly and CompanyInventors: LaVerne D. Boeck, Gary G. Marconi, Marvin M. Hoehn
-
Patent number: 4552842Abstract: A novel antitumor agent designated herein as rebeccamycin is produced by fermentation of Nocardia aerocolonigenes (ATCC 39243). Rebeccamycin and its 5'-N-methyl and 5',2",3",6"-tetraacetate derivatives exhibit activity against experimental animal tumor systems.Type: GrantFiled: April 13, 1984Date of Patent: November 12, 1985Assignee: Bristol-Myers CompanyInventors: Donald E. Nettleton, Jr., James A. Bush, William T. Bradner, Terrence W. Doyle
-
Patent number: 4537957Abstract: 23-Demycinosyltylosin (DMT) which has the formula: ##STR1## 20-dihydro-DMT, specified acyl ester derivatives, and their acid addition salts are useful antibacterial agents. Improved methods of making 5-O-mycaminosyltylonolide (OMT) and 20-dihydro-OMT by mild acid hydrolysis of DMT and 20-dihydro-DMT, respectively, are included.Type: GrantFiled: June 13, 1983Date of Patent: August 27, 1985Assignee: Eli Lilly and CompanyInventors: Richard H. Baltz, Gene M. Wild, Eugene T. Seno
-
Patent number: 4518589Abstract: A novel antibiotic complex designated BBM-2478 is produced by fermentation of an actinomycete strain J907-21 (ATCC 39417). The complex may be separated chromatographically into two bioactive components designated BBM-2478A and BBM-2478B. The BBM-2478A component displays both antibacterial and antitumor activity while the BBM-2478B component has antibacterial activity.Type: GrantFiled: October 3, 1983Date of Patent: May 21, 1985Assignee: Bristol-Myers CompanyInventors: Masataka Konishi, Koko Sugawara, Takeo Miyaki, Hiroshi Kawaguchi